Long-acting growth hormone in 2022  

作　　者：Margaret Steiner Jacklyn Frank Paul Saenger 

机构地区：[1]NYU Langone Health-Long Island,101 Mineola Boulevard,Mineola,New York,USA

出　　处：《Pediatric Investigation》2023年第1期36-42,共7页儿科学研究（英文）

摘　　要：After the isolation of pituitary growth hormone(GH)in 1957,this form of GH,always in limited supply,was the only drug available for the treatment of GH deficiency.In 1985,recombinant GH became available,and the modalities of GH therapies changed dramatically as the supply was unlimited.New indications for GH in pediatrics and adult medicine were developed.Treatment was daily.Now in 2021 long-acting GH(LAGH)became available the world over making GH therapy more patient-friendly and even showing slightly greater efficacy than daily GH therapy.We are now entering a new era of LAGH therapy for pediatric and adult use with new formulations of GH,which will predictably be the preferred form of GH therapy for years to come increasing adherence to GH therapy and possibly even efficacy,that is,better growth rate.The continued availability of new safety data will further solidify the use of LAGH in clinical medicine.

关 键 词：Long-acting growth hormone Pegylation of growth hormone Prodrug of growth hormone Albumin binding of growth hormone Growth hormone fusion proteins 

分 类 号：R977.1[医药卫生—药品]